Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).

Daniel M. Geynisman,Brian T. Kadow,Brian Shuch,Stephen A. Boorjian,Surena F. Matin,Edward N. Rampersaud,Daniel McClean,Barton Milestone,Elizabeth R. Plimack,Matthew Zibelman,Alexander Kutikov,Marc C. Smaldone,David Y.T. Chen,Rosalia Viterbo,Shreyas Joshi,Richard E. Greenberg,Lois Malizzia,Thomas McGowan,Eric A. Ross,Robert G. Uzzo

Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).

2019

560Background: Level I evidence exists demonstrating the efficacy of the mTOR inhibitor everolimus (EVE) in decreasing tumor volume of syndromic angiomyolipomas (AMLs) among patients with Tuberous ...

Keywords:

Pathology
Oncology
Everolimus
SAGE
Medicine
Internal medicine
Discovery and development of mTOR inhibitors
growth kinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations